Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing
I'm PortAI, I can summarize articles.
Dec 31 (Reuters) - Climb Bio Inc:CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILINGCLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO’S BUDOPRUTUG DRUG CANDIDATE IS NOT “PRODUCT” UNDER APACLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG Source text: Further company coverage:
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments